Affimed ( NASDAQ:AFMD – Free Report ) – Equities research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for shares of Affimed in a research note issued on Tuesday, November 19th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earnings per share of ($4.
06) for the year, down from their prior forecast of ($3.71). Cantor Fitzgerald currently has a “Overweight” rating on the stock.
The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. Affimed ( NASDAQ:AFMD – Get Free Report ) last announced its quarterly earnings results on Thursday, September 5th.
The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.
09). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.
67 million. Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.
84%. View Our Latest Report on AFMD Affimed Price Performance Shares of AFMD stock opened at $2.62 on Friday.
Affimed has a 12-month low of $2.61 and a 12-month high of $8.95.
The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.
93. The business has a 50 day simple moving average of $3.38 and a 200 day simple moving average of $4.
43. Institutional Investors Weigh In On Affimed Several hedge funds have recently modified their holdings of AFMD. Choreo LLC purchased a new position in Affimed in the 2nd quarter worth about $54,000.
Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period.
Jane Street Group LLC purchased a new position in shares of Affimed in the third quarter worth approximately $44,000. FMR LLC lifted its position in shares of Affimed by 30.0% in the 3rd quarter.
FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares in the last quarter. Finally, Point72 Asset Management L.P.
boosted its stake in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.
P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. 30.
82% of the stock is owned by hedge funds and other institutional investors. Affimed Company Profile ( Get Free Report ) Affimed N.V.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. Featured Stories Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.
com's FREE daily email newsletter ..
Business
Cantor Fitzgerald Decreases Earnings Estimates for Affimed
Affimed (NASDAQ:AFMD – Free Report) – Equities research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for shares of Affimed in a research note issued on Tuesday, November 19th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earnings per share of ($4.06) for the year, down from their prior [...]